secwatch.observer — SEC 8-K summary
======================================

Issuer:     Silexion Therapeutics Corp (SLXN)
CIK:        0002022416
Form:       8-K
Filed at:   2026-08-13T21:06:26+00:00
Accession:  0001178913-26-004128
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Silexion restates FY2025 financials for 1-for-10 reverse split; auditor flags going concern
--------------------------------------------------------------------------------

- FY2025 net loss $11.9M vs $16.5M in 2024; operating loss $11.6M vs $12.6M.
- Cash and equivalents $5.99M at Dec 31, 2025, up from $1.19M; total assets $7.2M.
- Auditor expresses substantial doubt about ability to continue as going concern due to recurring losses.
- 1-for-10 reverse split effective May 28, 2026; all share and per-share data retroactively adjusted.
- R&D spend rose to $7.1M from $5.8M; G&A fell to $4.5M from $6.8M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004128/0001178913-26-004128-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2022416/000117891326004128/zk2635957.htm
  HTML page:      https://secwatch.observer/filing/0001178913-26-004128

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer